Osel Inc. and March of Dimes Announce Groundbreaking Phase 2b Trial of Microbiome-based Therapy Targeting Preterm Birth Prevention

MOUNTAIN VIEW, Calif. & ARLINGTON, Va. & LONDON, May 13, 2026--Osel Inc., a clinical‑stage biopharma leader in live ...
Healio

LACTIN-V reduces recurrent bacterial vaginosis risk following cure with antibiotics

Please provide your email address to receive an email when new articles are posted on . A live biotherapeutic product significantly reduced the risk for recurrent BV in women who were clinically cured ...
The New England Journal of Medicine

Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis

Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new ...
Business Wire

Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Osel, Inc. today announced the initiation of a Phase 2b clinical study of its lead product candidate, LACTIN-V, to prevent the recurrence of bacterial vaginosis ...
Business Wire

Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Osel, Inc. today announced the first patient has been dosed in a new clinical study launched in collaboration with five Danish fertility clinics and Statens ...
Medscape

Probiotic May Help Prevent Recurrent Urinary Tract Infection

April 20, 2011 — In a randomized, double-blind phase 2 study, an intravaginal probiotic composed of Lactobacillus crispatus CTV-05 (Lactin-V, Osel Inc) reduced the rate of recurrent urinary tract ...